We could not find any results for:
Make sure your spelling is correct or try broadening your search.
By Chris Wack Immuron Ltd. shares were up 45% to $2.71 after the company said that the U.S. Naval Medical Research Center has received approval from the U.S. Food and Drug Administration to...
By Chris Wack Immuron Ltd. said Monday that the U.S. Naval Medical Research Center has received approval from the U.S. Food and Drug Administration to proceed with the clinical evaluation of a new...
By Chris Wack Immuron Ltd. shares were up 40% to $2.26 after the company said Friday that it has received approval from the U.S. Food and Drug Administration to proceed with the clinical...
By Chris Wack Immuron Ltd. said Friday that it has received approval from the U.S. Food and Drug Administration to proceed with the clinical evaluation of Travelan. The company said the...
By Chris Wack Immuron Ltd. said Tuesday that it has executed a master service agreement with U.S.-based Pharmaron CPC Inc. The biopharmaceutical company said its clinical trial agreement will...
By Connor Hart Immuron Ltd. on Tuesday said the U.S. Naval Medical Research Center received feedback from the U.S. Food and Drug Administration that its investigational new drug application...
By Chris Wack Immuron Ltd. said a new request for $4 million in funding has been considered to be "eligible for award" by the Medical Technology Enterprise Consortium, a U.S. Defense...
By Chris Wack Immuron Ltd. shares were up 40% to $3.66 after the company said it was awarded 4.8 million Australian dollars ($3.4 million) in funding in a new research agreement with the U.S...
By Chris Wack Immuron Ltd. said it was awarded 4.8 million Australian dollars ($3.4 million) in funding in a new research agreement with the U.S Department of Defense a study to clinically...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.005 | -6.32911392405 | 0.079 | 0.08 | 0.074 | 118775 | 0.07775123 | DE |
4 | -0.003 | -3.8961038961 | 0.077 | 0.08 | 0.072 | 76217 | 0.07581676 | DE |
12 | -0.025 | -25.2525252525 | 0.099 | 0.11 | 0.072 | 255947 | 0.0875256 | DE |
26 | -0.015 | -16.8539325843 | 0.089 | 0.11 | 0.072 | 217347 | 0.09159987 | DE |
52 | -0.002 | -2.63157894737 | 0.076 | 0.17 | 0.065 | 552151 | 0.11670784 | DE |
156 | -0.046 | -38.3333333333 | 0.12 | 0.17 | 0.065 | 340156 | 0.11030175 | DE |
260 | -0.056 | -43.0769230769 | 0.13 | 0.95 | 0.05 | 580020 | 0.27917914 | DE |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions